Mersana Therapeutics Operating Margin 2016-2021 | MRSN

Current and historical operating margin for Mersana Therapeutics (MRSN) over the last 10 years. The current operating profit margin for Mersana Therapeutics as of September 30, 2021 is -348653.50%.
Mersana Therapeutics Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2021-09-30 $0.00B $-0.15B inf%
2021-06-30 $0.00B $-0.13B inf%
2021-03-31 $0.00B $-0.11B -10600.00%
2020-12-31 $0.00B $-0.09B -8800.00%
2020-09-30 $0.00B $-0.08B -7600.00%
2020-06-30 $0.00B $-0.07B -3550.00%
2020-03-31 $0.00B $-0.07B -6900.00%
2019-12-31 $0.04B $-0.03B -73.81%
2019-09-30 $0.04B $-0.04B -86.05%
2019-06-30 $0.04B $-0.04B -84.09%
2019-03-31 $0.05B $-0.03B -66.67%
2018-12-31 $0.01B $-0.07B -660.00%
2018-09-30 $0.01B $-0.06B -475.00%
2018-06-30 $0.02B $-0.05B -300.00%
2018-03-31 $0.02B $-0.04B -275.00%
2017-12-31 $0.02B $-0.04B -229.41%
2017-06-30 $0.01B $-0.02B -209.09%
2017-03-31 $0.01B $-0.02B -138.46%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.500B $0.001B
Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09